Immune checkpoint inhibitors are superior to docetaxel as second-line therapy for patients with non-small cell lung carcinoma. [electronic resource]

By: Producer: 20190509Description: 178-179 p. digitalISSN:
  • 1542-4863
Subject(s): Online resources: In: CA: a cancer journal for clinicians vol. 68
Tags from this library: No tags from this library for this title. Log in to add tags.
Star ratings
    Average rating: 0.0 (0 votes)
No physical items for this record

Publication Type: Journal Article; Comment

There are no comments on this title.

to post a comment.